ISS and Glass Lewis Recommend Cholestech Stockholders Vote 'F...( HAYWARD Calif. Sept. 10 /- Choles...),Health

HAYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Cholestech Corporation (Nasdaq: CTEC) today announced that Institutional Shareholder Services (ISS) and Glass Lewis, two leading independent proxy advisory firms, recommended that Cholestech stockholders vote "FOR" the merger transaction between Cholestech and Inverness Medical Innovations, Inc. (Amex: IMA) and Iris Merger Sub, Inc., a wholly owned subsidiary of Inverness. Cholestech stockholders should vote promptly so that their votes can be counted at the company's September 12, 2007 Special Meeting of Stockholders.

"We are very pleased that ISS and Glass Lewis have confirmed our board of directors' view that this transaction is in the best interests of our stockholders," said Warren E. Pinckert II, Cholestech's President and CEO.

Stockholders of record as of the close of business on August 1, 2007, are entitled to vote on the proposed merger. Under the terms of the merger agreement, as announced on June 4, 2007, Cholestech stockholders will receive .43642 shares of Inverness common stock per share after closing.

Cholestech's board of directors has carefully reviewed and considered the terms and conditions of the merger agreement. Based on its review, Cholestech's board of directors has unanimously determined that the merger is advisable, fair and in the best interests of Cholestech and its stockholders and recommends that stockholders vote for approval of the principal terms of the merger and for the adjo
'/>"/>